Tasigna (Nilotinib)
The Tasigna MDL was centralized in August 2021 to coordinate claims that nilotinib, a tyrosine kinase inhibitor used to treat chronic myeloid leukemia, is associated with accelerated atherosclerosis and related vascular injury, including peripheral artery disease and other cardiovascular complications, allegedly without adequate warning to prescribers and patients. With 36 actions pending, this remains one of the smaller active products-liability dockets, consistent with a narrower patient population — chronic myeloid leukemia is a comparatively uncommon cancer — relative to dockets built around widely prescribed medications.
What most distinctly shapes resolution risk in this docket is a differential-causation challenge layered on top of the general-causation question common to any drug-injury claim: because claimants are being treated for a serious cancer and often have other cancer-treatment-related or independent risk factors for cardiovascular disease, establishing that a specific vascular injury is attributable to nilotinib specifically — rather than to the underlying disease, other medications, or unrelated risk factors — requires a more individualized causation analysis than is typical in some other drug-injury mass torts.
That individualized-causation profile, combined with the docket's small and stable size, suggests a litigation likely to be resolved primarily through claim-by-claim development rather than through a large-scale bellwether-to-settlement-fund process built around a common general-causation finding — the population and evidentiary structure here do not lend themselves to the same kind of aggregate resolution mechanism seen in larger, more homogeneous mass torts.
Criterica Intelligence treats differential-causation complexity — where an alleged injury must be distinguished from competing causes tied to a claimant's underlying condition or other treatment — as a distinct structural risk factor from general causation itself, and tracks that distinction across every active MDL where it is relevant, including this one.
It consolidates claims that nilotinib, a leukemia medication marketed as Tasigna, is linked to accelerated atherosclerosis and related vascular injury, allegedly without adequate warning to prescribers and patients.
Chronic myeloid leukemia, the condition nilotinib treats, affects a comparatively small patient population relative to more widely prescribed medications, which naturally limits the size of the claims population in this docket.
It proceeds toward an individual trial, where the central issue is typically whether the claimant's specific vascular injury can be attributed to nilotinib rather than to other cancer-treatment-related or independent risk factors.
Because claimants often have competing potential causes for their vascular injury tied to their underlying cancer or its treatment, proving the case requires distinguishing a nilotinib-specific effect from those other possible causes, rather than relying on a single shared causation theory.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.